Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II irinotecan and temozolomide added to standard therapy for newly diagnosed Ewing sarcoma
MOH_2019-06-24_007221Phase 2Not yet recruiting
- Sponsor
- ד"ר דרור רביב
- Start
- Nov 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan and temozolomide in Ewing sarcoma (2 cohorts), sponsored by ד"ר דרור רביב. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
irinotecantemozolomide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on MOH_2019-06-24_007221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-24_007221.